Lyn­dra’s long-act­ing risperi­done for­mu­la­tion hits PhI­II schiz­o­phre­nia tri­al end­points

Lyn­dra Ther­a­peu­tics’ schiz­o­phre­nia drug can­di­date has passed its late-stage clin­i­cal test ac­cord­ing to in­ter­im da­ta, prompt­ing an ear­ly end to the study and prepa­ra­tions for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER